Edwards Lifesciences Corp (NYSE:EW) has earned a consensus rating of “Buy” from the twenty-five brokerages that are presently covering the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $119.88.

EW has been the topic of several research analyst reports. BTIG Research cut Edwards Lifesciences Corp from a “buy” rating to a “neutral” rating in a research report on Thursday, February 2nd. They noted that the move was a valuation call. Leerink Swann cut Edwards Lifesciences Corp from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 2nd. Northland Securities reaffirmed a “positive” rating and set a $105.00 price target on shares of Edwards Lifesciences Corp in a research report on Thursday, February 2nd. Canaccord Genuity set a $140.00 price target on Edwards Lifesciences Corp and gave the company a “buy” rating in a research report on Thursday, February 2nd. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $100.00 price target on shares of Edwards Lifesciences Corp in a research report on Sunday, February 5th.

In other news, VP Donald E. Bobo, Jr. sold 13,720 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $90.01, for a total transaction of $1,234,937.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Bernard J. Zovighian sold 18,050 shares of the stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $109.21, for a total value of $1,971,240.50. The disclosure for this sale can be found here. Insiders sold a total of 255,041 shares of company stock worth $27,225,450 over the last 90 days. Corporate insiders own 2.37% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Edwards Lifesciences Corp by 2,184.9% in the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after buying an additional 13,390,818 shares during the period. Norges Bank purchased a new position in shares of Edwards Lifesciences Corp during the fourth quarter valued at approximately $217,484,000. Alliancebernstein L.P. raised its position in shares of Edwards Lifesciences Corp by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after buying an additional 1,459,921 shares during the period. MARSHALL WACE ASIA Ltd purchased a new position in shares of Edwards Lifesciences Corp during the first quarter valued at approximately $126,959,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Edwards Lifesciences Corp during the first quarter valued at approximately $126,959,000. Hedge funds and other institutional investors own 83.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corp (EW) Given Average Rating of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/05/23/edwards-lifesciences-corp-ew-given-average-rating-of-buy-by-analysts.html.

Edwards Lifesciences Corp (NYSE:EW) traded down 0.48% during midday trading on Tuesday, reaching $113.54. The company had a trading volume of 999,106 shares. The stock’s 50 day moving average is $103.82 and its 200 day moving average is $95.03. Edwards Lifesciences Corp has a 12-month low of $81.12 and a 12-month high of $121.75. The firm has a market capitalization of $23.82 billion, a price-to-earnings ratio of 37.75 and a beta of 0.53.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings data on Tuesday, April 25th. The medical research company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The business had revenue of $883.50 million for the quarter, compared to analysts’ expectations of $776.51 million. During the same quarter in the previous year, the firm earned $0.71 earnings per share. The business’s revenue was up 26.7% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences Corp will post $3.53 earnings per share for the current year.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

12 Month Chart for NYSE:EW

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.